DL-Tryptophan
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | DL-Tryptophan (racemic tryptophan) |
|---|---|
| Chemical class | Racemic mixture of D- and L-tryptophan — aromatic amino acid |
| CAS | 54-12-6 (DL-tryptophan) · 73-22-3 (L-tryptophan) · 153-94-6 (D-tryptophan) |
| Molecular weight | 204.23 g/mol |
| D-isomer conversion | Partial, via D-amino acid oxidase — less efficient than D-methionine |
| Regulatory note | Food and supplement use of the racemate is restricted in many markets |
| Claim strength | High for the partial conversion; low for nutritional equivalence to L- |
| Buy from Herbuno | DL-Tryptophan 99% Powder · L-Tryptophan 99% Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot |
Name origin: The racemate of tryptophan, which Hopkins and Cole named in 1901 from the Greek tryptos, pounded, after the trypsin digestion by which they isolated it. The racemic form is a product of chemical synthesis rather than biology: routes from indole via the Strecker or hydantoin chemistry are not stereoselective and yield both enantiomers in equal measure.
Why the racemate exists: Cost and route. Chemical synthesis from indole and an appropriate three-carbon partner is cheaper than fermentation at some scales and yields the racemate inherently, so DL-tryptophan has historically been the economical article where the isomer purity was not required. Enantioselective enzymatic routes and fermentation now supply the L-form directly, which has narrowed the price gap considerably.
The D-isomer question: Unlike D-methionine, which converts to the L-form efficiently, D-tryptophan's conversion is partial. D-amino acid oxidase deaminates it to indole-3-pyruvate, which can be transaminated to L-tryptophan, but the efficiency is lower and species-dependent, and a substantial fraction is excreted or metabolised by other routes including by gut microbiota. D-tryptophan also has properties of its own: it is intensely sweet, estimated at many times the sweetness of sucrose, which is a curiosity rather than a commercial sweetener application.
Commercial source: DL-tryptophan is produced by chemical synthesis from indole. It shares L-tryptophan's quality history: the 1989 eosinophilia-myalgia syndrome outbreak established tryptophan as a material where process-related impurity control, particularly of dimers and condensation products, is the governing quality question rather than assay.
Evidence for DL-Tryptophan Applications
D-tryptophan conversion is partial, and the racemate should not be treated as nutritionally equivalent to the L-form. D-amino acid oxidase deaminates D-tryptophan to indole-3-pyruvate, which can be transaminated to L-tryptophan, so some conversion occurs; but efficiency is lower than for D-methionine, varies by species, and a meaningful fraction is excreted unchanged or diverted to other routes including microbial metabolism. The defensible position is that DL-tryptophan delivers somewhere between half and most of the nutritional value of an equivalent weight of L-, with the figure not well established in humans. Claim strength: Moderate.
Regulatory restriction is usually the deciding factor rather than the biochemistry. Food and supplement use of DL-tryptophan is restricted or not permitted in many jurisdictions, where the L-form specifically is the approved article; feed use is more widely permitted. The position differs by country and by product category, and the partial conversion does not settle it. For any product intended across several markets, resolve the most restrictive classification before formulating, because this is not a question a reformulation answers. Claim strength: High.
The 1989 EMS impurity legacy applies to the racemate as fully as to the L-form, and arguably more so given the synthetic route. The outbreak affected over 1,500 people in the United States with several dozen deaths and was traced epidemiologically to tryptophan from one manufacturer after a process change, with tryptophan dimers including 1,1'-ethylidenebis-L-tryptophan among the candidate contaminants. Causality was never formally established, but tryptophan in any isomeric form is a material where the impurity profile, not the assay, is the quality question. Claim strength: High.
The useful comparison is with DL-methionine, and it runs the other way. DL-methionine is a legitimate economic choice because D-methionine converts efficiently to the L-form in liver and kidney, which is why the racemate is standard in feed and acceptable in many food applications. DL-tryptophan's D-isomer converts less efficiently, so the economic case is weaker on nutritional grounds alone, before the regulatory restriction is considered. Reasoning by analogy from methionine to tryptophan produces the wrong conclusion. Claim strength: High.
Tryptophan's own metabolic and formulation facts apply unchanged to the racemate. Around 95% of L-tryptophan catabolism proceeds down the kynurenine pathway to NAD⁺, with only approximately 1 to 2% going to serotonin; the niacin equivalence is roughly 60 milligrams tryptophan to 1 milligram niacin equivalent; and large neutral amino acid transport competition with branched-chains, tyrosine and phenylalanine means a dose taken with protein delivers much less centrally. The D-isomer does not participate in the serotonin pathway directly. Claim strength: High.
Feed use is where the racemate has a clear and uncontroversial application. Tryptophan is a limiting amino acid in some swine and poultry diets, DL-tryptophan is permitted in feed in most jurisdictions, and the partial D-isomer conversion is accounted for in feed formulation practice through bioefficacy factors rather than assumed equivalence. This is the market the racemate principally serves, and a quotation written against feed specification should not be transferred to a human application without revisiting both the grade and the regulatory position. Claim strength: High.
Sourcing DL-tryptophan from Herbuno. We supply DL-tryptophan and L-tryptophan at 99%.
Confirm the regulatory position before specifying the racemate: food and supplement use of DL-tryptophan is restricted or not permitted in many markets, where L- is the approved article, and the partial D-isomer conversion does not settle that. Do not reason from DL-methionine, where the D-isomer converts efficiently — tryptophan's does not. And specify the dimer and related-substance profile, not just assay. All lots ship with CoA and MSDS; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
DL-tryptophan is dosed as the free amino acid at 99%, with no salt conversion. On a nutritional basis it should not be dosed as equivalent to L-tryptophan: the D-isomer converts only partially, so the usable tryptophan from a given weight of racemate lies somewhere between half and most of the equivalent L- weight, and the figure is not well established in humans. In feed formulation the practice is to apply a bioefficacy factor rather than assume equivalence, and the same discipline is appropriate anywhere the racemate is permitted.
Regulatory classification should be settled first and is binary rather than negotiable. Food and supplement use of DL-tryptophan is restricted or not permitted in many jurisdictions, with the L-form the approved article; feed use is more widely permitted. Confirm the position country by country and category by category at the concept stage. Separately, tryptophan in any form still carries residual regulatory sensitivity in some markets as a legacy of the 1989 withdrawal, and that too differs by jurisdiction.
Impurity specification is the technical priority, as for the L-form. Require an HPLC impurity profile with a stated limit for tryptophan dimers and condensation products, the production route named, and contractual notification of any process change. For synthetic material, specify the indole-derived process impurities relevant to the route in use. A 99% assay certificate with no related-substance data is not an adequate specification for tryptophan in any isomeric form, and this is the one amino acid in the catalogue where that statement is not merely precautionary.
Handling matches the L-form. DL-tryptophan is poorly soluble in water at around 1 gram per 100 millilitres at room temperature, which limits liquid applications; it is stable to heat and across a broad pH range but light-sensitive, the indole ring being susceptible to photo-oxidation, so opaque or amber packaging and protection during processing are advisable. Taste is bitter. It participates in Maillard reactions and the indole ring can generate characteristic off-notes in thermally processed formats.
For analytical control, specify the isomeric form explicitly with optical rotation or a chiral method to confirm it, since L- and DL- cannot be distinguished by a standard assay and the price difference creates a substitution incentive. The direction of risk here is the reverse of most categories: the racemate is cheaper, so the exposure is DL- supplied against an L- specification, which matters both nutritionally and for regulatory compliance. Standard coverage includes heavy metals, residual solvents, microbiological limits, loss on drying and sulphated ash, with the grade stated explicitly given the feed-dominated market.
On form selection, the honest guidance is narrower than for most racemates in this catalogue. DL-tryptophan is the correct specification for permitted feed applications, where it is economical and the bioefficacy discount is handled routinely. For human food and supplement use, the L-form is the appropriate specification in most markets as a matter of regulation and is the safer choice as a matter of nutritional accounting. The economic case for the racemate in human applications is weaker than the DL-methionine analogy suggests, and narrower still once the regulatory position is confirmed. Where a customer asks for DL- to save cost on a human product, the conversation worth having is about the market authorisation rather than the price.
Frequently Asked Questions — DL-Tryptophan
Is DL-tryptophan equivalent to L-tryptophan?
No. D-amino acid oxidase deaminates D-tryptophan to indole-3-pyruvate, which can be transaminated to L-, so some conversion occurs — but efficiency is lower than for D-methionine, species-dependent, and a meaningful fraction is excreted or diverted to microbial metabolism. Usable tryptophan sits somewhere between half and most of an equivalent L- weight.
Why can I use DL-methionine but not DL-tryptophan?
Because the D-isomers behave differently. D-methionine converts efficiently in liver and kidney, which is why that racemate is standard in feed and acceptable in many food applications. D-tryptophan's conversion is partial. Reasoning by analogy from methionine to tryptophan gives the wrong answer, and the regulatory position differs too.
Can I use it in a human product?
Check the market first. Food and supplement use of DL-tryptophan is restricted or not permitted in many jurisdictions, where L- is the approved article; feed use is more widely permitted. The partial conversion does not settle the regulatory question, and no reformulation answers it. Resolve the most restrictive target market at concept stage.
Does the 1989 EMS history apply to the racemate?
Fully, and arguably more given the synthetic route. The outbreak affected over 1,500 people in the US with several dozen deaths, traced to material from one manufacturer after a process change, with tryptophan dimers among the candidate contaminants. Tryptophan in any isomeric form is a material where the impurity profile, not the assay, is the quality question.
What should the certificate show?
An HPLC impurity profile with a stated dimer and related-substance limit, the production route named, the route-specific indole-derived impurities for synthetic material, and contractual process-change notification. Plus optical rotation to confirm the isomeric form — the racemate is cheaper, so the substitution risk runs toward DL- against an L- specification.
Where is the racemate genuinely appropriate?
Permitted feed applications. Tryptophan is limiting in some swine and poultry diets, DL-tryptophan is permitted in feed in most jurisdictions, and the partial conversion is handled through bioefficacy factors rather than assumed equivalence. A quotation written to feed specification should not transfer to a human application without revisiting grade and status.